Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
All News
Article
Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Article
Methotrexate Impairs COVID Vax Response
MedPage Today
One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.
#OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #ax-SpA patients: Low PCS were more often in remission as high PCS in RA & ax-SpA. PCS was associated with remission rates in RA and ax-SpA, but not in PsA #EULAR2021 @RheumNow https://t.co/MYiLmPPbDN
Meral K. El Ramahi, MD
Tweet
#EULAR2021: Reduced likelihood of reaching disease remission in patients with RA or PsA who have concomitant depression and anxiety per prospective NOR-DMARD study. Social state and mental health factors play an important role in noresponse in T2T approach. @RheumNow https://t.co/Vl0Xkz2SNF
Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla
Aurelie Najm
Tweet
Don’t forget to detect cardiac abnormalities in your #RA and #PsA patients! Systematic transthoracic echocardiogram show higher prevalence of diastolic dysfunction, mild mitral and pulmonary valve regurgitation vs. matched controls. #EULAR2021 @RheumNow #POS1392 https://t.co/UsvbEKBRUY
Richard Conway
Tweet
Dr Kragsnaes presents counter-intuitive data on the gut microbiome. Faecal microbiota transplant ineffective in treating active peripheral psoriatic arthritis, leading to WORSE outcomes. But maybe this also tells us something? @RheumNow #EULAR2021 Abstr#OP0010 https://t.co/nvDvO4Gfxc
OP0010 at #EULAR2021. FLORA trial: Fecal microbiota transplant as add-on Rx to MTX. Small trial showing time-to-event curves show inferiority to sham but good safety. Fascinating concept exploring gut-joint interaction. @RheumNow. https://t.co/BIOmA5z6vK
Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx
Differences in PROs found in CORRONA(now CorEvitas) PsA/SpA registry Ax-PsA and AxSpA patients. Can we better use PROs for disease characterization/differentiation? Abstract #OP0049 #EULAR2021 @RheumNow https://t.co/uHW2FQe0A5 https://t.co/HuPPUTAC9Z
Plenary abstract #OP0010: Fecal microbiota transplant (FMT) found to be inferior to sham in treating active peripheral PsA. No SAEs in patients treated with FMT. @RheumNow #EULAR2021 https://t.co/a5HgrJ4y1C https://t.co/Jk9FQZdn4B
Does Fecal transplant work to treat PsA?
per FLORA trial: No benefits from fecal microbiotia transplantation vs sham in PsA w/ active dz despite MTX (limited by small size, high placebo response) - Dr. M Kragsnaes Abstr#OP0010 #EULAR2021 @rheumnow https://t.co/I7PsWgK9uA https://t.co/OKC4QcH8Nq
The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden in PsA patients. #EULAR2021 @RheumNow Poster #POS0194 https://t.co/FaIZ7LcoNj
Dr. Angioni et al characterize PsA clinical remission on a molecular level. c-FOS and CCD50 (YMER) appear to be two key genes. #EULAR2021 poster #POS0409 @RheumNow https://t.co/4lytsgjdzj https://t.co/ySjIXBHTA0
Hands-Down Rheumatology - Gout doesnt get to the hands until its done its damage below (MTP, ankle, knee) and usually only in those with severe tophaceous goutdCan also present as dactylitis or Carpal tunnel. Women on diuretics w/ CKD can get gout in Nodal OA joints https://t.co/EpBpdC31J6
Danish registry study of 1,356 psoriasis and 370 PsA pts shows increased odd of coronary disease by CT Calcium scores - psoriasis w CACS ≥ 400 OR 1.25 (1.04-1.50); PsA CACS>0 OR 1.28 (1.00-1.64). Nearly a 49% incr risk in PSO (HR 1.49) https://t.co/jQSAV66TAi
